Related Experiment Video
Updated: Jun 14, 2025
11:13
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
1.5K
Salidroside alleviates simulated microgravity-induced bone loss by activating the Nrf2/HO-1 pathway
Nan Wang1, Zhuan Zuo1, Tong Meng2
1Department of Orthopedic Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Journal of Orthopaedic Surgery and Research
|September 1, 2024
Summary
Salidroside effectively combats microgravity-induced bone loss by promoting bone formation and reducing resorption. This compound works by activating the Nrf2/HO-1 pathway, offering a potential treatment for astronauts.
Area of Science:
- Space Medicine
- Bone Biology
- Pharmacology
Background:
- Microgravity exposure causes significant bone loss, posing risks to astronaut health.
- Current treatments for space-related bone loss have limitations.
Purpose of the Study:
- To investigate salidroside's potential to mitigate microgravity-induced bone loss.
- To elucidate the underlying mechanisms of salidroside's effects.
Main Methods:
- In vivo studies utilized hindlimb unloading (HLU) to simulate microgravity in rats.
- In vitro studies employed the Rotary Cell Culture System (RCCS) for simulated microgravity in MC3T3-E1 cells.
- The Nrf2 inhibitor ML385 was used to assess pathway involvement.
Main Results:
- Salidroside treatment improved bone density, microstructure, and biomechanical properties in HLU rats.
- Salidroside promoted osteoblast differentiation and osteogenic gene expression under simulated microgravity.
- The protective effects of salidroside were dependent on the Nrf2/HO-1 pathway, as shown by the ML385 inhibitor study.
Conclusions:
- Salidroside demonstrates significant potential for preventing and treating bone loss in astronauts.
- The Nrf2/HO-1 pathway is a key therapeutic target for counteracting microgravity-induced bone damage.
